Lei Lei Wu is a News Reporter at Endpoints News. She specializes in reporting on medicine and healthcare, with a focus on topics such as the FDA, biotech, markets, and alternative medicine. Lei Lei's work has been featured in Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lei Lei Wu's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly on biotechnology, pharmaceutical companies, gene therapy, clinical trials, and drug development. The majority of her articles are based on press releases and cite data.
Given this focus, she would likely be interested in receiving pitches related to new developments in biotechnology or pharmaceuticals backed by solid data or press releases. Pitches offering insights from experts within these fields regarding groundbreaking studies or significant advancements in drug development may resonate with her. Additionally, providing access to exclusive data or early access to important press releases could enhance the effectiveness of outreach efforts.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, suggesting that the therapy is durable beyond the …
By: Lei Lei Wu
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, showing over 60% fetal hemoglobin expression and resolved anemia. The company joins bluebird bio and Vertex/CRISPR Therapeutics in developing sickle cell treatments. One patient died from chemotherapy-related complications.
By: Gene Tx
SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson …
By: Lei Lei Wu
The FDA approved Checkpoint Therapeutics’ anti-PD-L1 antibody cosibelimab in a form of advanced skin cancer, the company announced Friday. The immune checkpoint drug will be marketed as Unloxcyt and will be administered as an IV infusion.
As interest grows in the ability to leverage certain ringed molecules as drugs, Orbis Medicines has raised €90 million in new funding less than a …
By: Lei Lei Wu
Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area of focus for the drugmaker ...
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The biotech is developing what it calls logic-gated cell …
By: Lei Lei Wu
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it plans to move forward into pivotal studies. However, the company’s shares fell Friday morning,
Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its commercial Alzheimer's diagnostics business. …
By: Gene Tx, Max Gelman
US regulators have rejected a T cell therapy for a rare and serious transplant complication related to Epstein-Barr virus from Atara Biotherapeutics and Pierre Fabre …
(833) 317-6278 
